Statins were described as protective of ECs in both intestinal barrier and BBB via NLRP3 inhibition, reviving the debate about the benefit of these drugs in AD (Schreibelt et al., 2006; Krylov et al., 2007; Varasteh et al., 2017). The gene discussed is NLRP3; the disease is Alzheimer disease.